search
Back to results

Multiple Dose Safety Tolerability, Pharmacokinetics And Midazolam Interaction In Healthy Overweight And Obese Subjects

Primary Purpose

Diabetes Mellitus Type 2

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
PF-05175157
Midazolam
Placebo
Midazolam
Sponsored by
Pfizer
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Diabetes Mellitus Type 2

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study:

  • Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead ECG and clinical laboratory tests).
  • Women must be of non childbearing potential.
  • Body Mass Index (BMI) of 25 to 35 kg/m2 inclusive; and a total body weight >50 kg (110 lbs).
  • An informed consent document signed and dated by the subject.
  • Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria:

  • Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
  • Evidence or history of any chronic ongoing or current pulmonary disease.
  • History of smoking in the past 5 years and a history of smoking more than 10 pack years, or history or evidence of habitual use of other (non smoked) tobacco or nicotine containing products. Active ocular disease including infection, glaucoma, seasonal allergies, dry eye symptoms or retinal/optic nerve disease.

Sites / Locations

  • Pfizer Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

PF-05175157, Midazolam

Placebo, Midazolam

Arm Description

Day 0: Midazolam 2 mg administered alone Days 1-14: 200 mg PF-05175157 administered BID Day 11: Midazolam and PF-05175157

Day 0: Midazolam 2 mg administered alone Days 1-14: Placebo administered BID Day 11: Midazolam and Placebo

Outcomes

Primary Outcome Measures

Maximum Observed Plasma PF-05175157 Concentration (Cmax)
Single Dose
Area Under the Curve from Time Zero to end of dosing interval for PF-05175157 (AUCtau)
Single Dose
Time to Reach Maximum Observed Plasma PF-05175157 Concentration (Tmax)
Single Dose
Maximum Observed Plasma PF-05175157 Concentration (Cmax)
Steady State
Area Under the Curve from Time Zero to end of dosing interval (AUCtau) for PF-05175157
Steady State
Time to Reach Maximum Observed Plasma PF-05175157 Concentration (Tmax)
Steady State
Apparent Oral Clearance of PF-05175157 (CL/F)
Accumulation Ratio of PF-05175157 (Rac)
Plasma Decay Half-Life of PF-05175157 (t1/2)
Apparent Volume of Distribution of PF-05175157 (Vz/F)
Urinary Recovery for PF-05175157 (AE24)
Amount of PF-05175157 recovered in urine over 24 hours
Renal Clearance for PF-05175157 (CLr)
Area Under the Curve From Time Zero to Last Quantifiable Concentration for midazolam [AUC (0-t)]
Area Under the Curve From Time Zero to Extrapolated Infinite Time for midazolam [AUC (0 - inf)]
Maximum Observed Plasma Concentration for midazolam (Cmax)
Time to Reach Maximum Observed Plasma midazolam Concentration (Tmax)
Plasma Decay Half-Life of midazolam (t1/2)
Fasting triglycerides
Total cholesterol
LDL cholesterol
HDL cholesterol

Secondary Outcome Measures

Full Information

First Posted
March 6, 2013
Last Updated
September 16, 2013
Sponsor
Pfizer
search

1. Study Identification

Unique Protocol Identification Number
NCT01807377
Brief Title
Multiple Dose Safety Tolerability, Pharmacokinetics And Midazolam Interaction In Healthy Overweight And Obese Subjects
Official Title
A Phase 1 Placebo-Controlled Study To Assess Safety, Tolerability, Pharmacokinetics And Effect On Midazolam Pharmacokinetics Of Multiple Oral Doses Of PF-05175157 Administered In A Tablet Formulation In Otherwise Healthy Overweight And Obese Subjects
Study Type
Interventional

2. Study Status

Record Verification Date
September 2013
Overall Recruitment Status
Completed
Study Start Date
April 2013 (undefined)
Primary Completion Date
August 2013 (Actual)
Study Completion Date
August 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Pfizer

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is designed to assess the safety, tolerability and pharmacokinetics of multiple oral 200-mg doses of PF-05175157 administered twice daily for 14 days in healthy overweight and obese subjects.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus Type 2

7. Study Design

Primary Purpose
Basic Science
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
15 (Actual)

8. Arms, Groups, and Interventions

Arm Title
PF-05175157, Midazolam
Arm Type
Experimental
Arm Description
Day 0: Midazolam 2 mg administered alone Days 1-14: 200 mg PF-05175157 administered BID Day 11: Midazolam and PF-05175157
Arm Title
Placebo, Midazolam
Arm Type
Experimental
Arm Description
Day 0: Midazolam 2 mg administered alone Days 1-14: Placebo administered BID Day 11: Midazolam and Placebo
Intervention Type
Drug
Intervention Name(s)
PF-05175157
Intervention Description
200 mg tablet administered twice per day for 14 days
Intervention Type
Drug
Intervention Name(s)
Midazolam
Intervention Description
2mg administered as single doses on Days 0 and 11
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
Placebo administered twice per day for 14 days
Intervention Type
Drug
Intervention Name(s)
Midazolam
Intervention Description
2mg administered as single doses on Days 0 and 11
Primary Outcome Measure Information:
Title
Maximum Observed Plasma PF-05175157 Concentration (Cmax)
Description
Single Dose
Time Frame
0 - 10 hrs postdose
Title
Area Under the Curve from Time Zero to end of dosing interval for PF-05175157 (AUCtau)
Description
Single Dose
Time Frame
0 - 10 hrs postdose
Title
Time to Reach Maximum Observed Plasma PF-05175157 Concentration (Tmax)
Description
Single Dose
Time Frame
0 - 10 hrs postdose
Title
Maximum Observed Plasma PF-05175157 Concentration (Cmax)
Description
Steady State
Time Frame
0 - 48 hours postdose
Title
Area Under the Curve from Time Zero to end of dosing interval (AUCtau) for PF-05175157
Description
Steady State
Time Frame
0 - 48 hours postdose
Title
Time to Reach Maximum Observed Plasma PF-05175157 Concentration (Tmax)
Description
Steady State
Time Frame
0 - 48 hours postdose
Title
Apparent Oral Clearance of PF-05175157 (CL/F)
Time Frame
0 - 48 hours postdose
Title
Accumulation Ratio of PF-05175157 (Rac)
Time Frame
0 - 10 hours postdose
Title
Plasma Decay Half-Life of PF-05175157 (t1/2)
Time Frame
0 - 48 hours postdose
Title
Apparent Volume of Distribution of PF-05175157 (Vz/F)
Time Frame
0 - 48 hours postdose
Title
Urinary Recovery for PF-05175157 (AE24)
Description
Amount of PF-05175157 recovered in urine over 24 hours
Time Frame
0 - 24 hours postdose
Title
Renal Clearance for PF-05175157 (CLr)
Time Frame
0 - 24 hours post dose
Title
Area Under the Curve From Time Zero to Last Quantifiable Concentration for midazolam [AUC (0-t)]
Time Frame
0 - 48 hours postdose
Title
Area Under the Curve From Time Zero to Extrapolated Infinite Time for midazolam [AUC (0 - inf)]
Time Frame
0 - 48 hours postdose
Title
Maximum Observed Plasma Concentration for midazolam (Cmax)
Time Frame
0 - 48 hours postdose
Title
Time to Reach Maximum Observed Plasma midazolam Concentration (Tmax)
Time Frame
0 - 48 hours post dose
Title
Plasma Decay Half-Life of midazolam (t1/2)
Time Frame
0 - 48 hours postdose
Title
Fasting triglycerides
Time Frame
14 days
Title
Total cholesterol
Time Frame
14 days
Title
LDL cholesterol
Time Frame
14 days
Title
HDL cholesterol
Time Frame
14 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study: Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead ECG and clinical laboratory tests). Women must be of non childbearing potential. Body Mass Index (BMI) of 25 to 35 kg/m2 inclusive; and a total body weight >50 kg (110 lbs). An informed consent document signed and dated by the subject. Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. Exclusion Criteria: Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing). Evidence or history of any chronic ongoing or current pulmonary disease. History of smoking in the past 5 years and a history of smoking more than 10 pack years, or history or evidence of habitual use of other (non smoked) tobacco or nicotine containing products. Active ocular disease including infection, glaucoma, seasonal allergies, dry eye symptoms or retinal/optic nerve disease.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pfizer CT.gov Call Center
Organizational Affiliation
Pfizer
Official's Role
Study Director
Facility Information:
Facility Name
Pfizer Investigational Site
City
Chula Vista
State/Province
California
ZIP/Postal Code
91911
Country
United States

12. IPD Sharing Statement

Links:
URL
https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1731021&StudyName=Multiple%20Dose%20Safety%20Tolerability%2C%20Pharmacokinetics%20And%20Midazolam%20Interaction%20In%20Healthy%20Overweight%20And%20Obese%20Subjects%0A
Description
To obtain contact information for a study center near you, click here.

Learn more about this trial

Multiple Dose Safety Tolerability, Pharmacokinetics And Midazolam Interaction In Healthy Overweight And Obese Subjects

We'll reach out to this number within 24 hrs